Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Sep 27;15(19):4741.
doi: 10.3390/cancers15194741.

The Evolution of Neo-Adjuvant Therapy in the Treatment of Oesophageal and Gastro-Oesophageal Junction Adenocarcinomas

Alexander A Dermanis  1 , Sivesh K Kamarajah  1   2 , Benjamin Tan  1
Affiliations
Review

The Evolution of Neo-Adjuvant Therapy in the Treatment of Oesophageal and Gastro-Oesophageal Junction Adenocarcinomas

Alexander A Dermanis et al. Cancers (Basel). .

Abstract

Historically, oesophageal and gastro-oesophageal junction adenocarcinomas were associated with a poor prognosis. The advent of neoadjuvant therapy has transformed the management of oesophageal and gastro-oesophageal junction adenocarcinomas further and offers the possibility to reverse disease progression, eliminate micrometastasis, and offer potentially better outcomes for these patients. This review provides an overview of landmark clinical trials in this area, with different treatment regimens considered over the years as well as potential therapeutic agents on the horizon that may transform the management of oesophageal and gastro-oesophageal junction adenocarcinomas further.

Keywords: adenocarcinoma; chemotherapy; gastro-oesophageal junction; immunotherapy; neoadjuvant; oesophagus; radiotherapy.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Overexpression of HER2 receptors on the cell surface, leads to receptors dimerising more frequently, causing autophosphorylation and activation of intracellular signalling processes promoting cell cycle progression and therefore carcinogenesis. This is therefore a potential target for monoclonal antibodies.
Figure 2
Figure 2
Binding of PD-1 to PD-L1 or PD-L2 downregulates the host immune response. Therefore, PD-1 or its associated ligands can be a potential target for monoclonal antibodies.
Figure 3
Figure 3
Summary of different Neoadjuvant strategies and key landmark trials to date [10,11,12,18,26,32,33,44,45,47,49,50,51].
See this image and copyright information in PMC

References

    1. Mukkamalla S.K.R., Recio-Boiles A., Babiker H.M. Esophageal Cancer. StatPearls Publishing; Treasure Island, FL, USA: 2023. [(accessed on 25 April 2023)]. Available online: https://www.ncbi.nlm.nih.gov/books/NBK459267/ - PubMed
    1. Van der Wilk B.J., Eyck B.M., Lagarde S.M., van der Gaast A., Nuyttens J.J.M.E., Wijnhoven B.P.L., van Lanschot J.J.B. The optimal neoadjuvant treatment of locally advanced esophageal cancer. J. Thorac. Dis. 2019;11((Suppl. S5)):S621–S631. doi: 10.21037/jtd.2018.11.143. - DOI - PMC - PubMed
    1. Li J., Ma S. History and current situation of neoadjuvant treatment for locally advanced esophageal cancer. Thorac. Cancer. 2021;12:2293–2299. doi: 10.1111/1759-7714.14069. - DOI - PMC - PubMed
    1. Nakayama K., Orihata H., Yamaguchi K. Surgical treatment combined with preoperative concentrated irradiation for esophageal cancer. Cancer. 1967;20:778–788. doi: 10.1002/1097-0142(1967)20:5<778::AID-CNCR2820200532>3.0.CO;2-B. - DOI - PubMed
    1. Shapiro J., van Lanschot J., Hulshof M., van Hagen P., van Berge Henegouwen M., Wijnhoven B.P.L., van Laarhoven H.W.M., Nieuwenhuijzen G.A.P., Hospers G.A.P., Bonenkamp J.J., et al. Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): Long-term results of a randomised controlled trial. Lancet Oncol. 2015;16:1090–1098. doi: 10.1016/S1470-2045(15)00040-6. - DOI - PubMed

LinkOut - more resources